Table 1.
Study on the correlation between the total number of CTCs and the clinical characteristics of HCC.
| Clinical characteristics | CTC≤13.3 | CTC>13.3 | P |
|---|---|---|---|
| Sex (Male/Female) | 97/16 | 44/3 | 0.166 |
| Age (≤60/>60 years) | 86/27 | 37/10 | 0.721 |
| Tumor Size (≤5/>5 cm) | 76/37 | 21/26 | 0.008 |
| Tumor Number (1/>1) | 90/23 | 32/15 | 0.118 |
| Differentiation (H/M/L) | 20/69/24 | 3/34/10 | 0.164 |
| BCLC Stage (A/B+C) | 72/41 | 21/26 | 0.026 |
| Metastasis (Yes/No) | 14/99 | 7/40 | 0.669 |
| AFP (≤400/>400 μg/L) | 72/41 | 32/15 | 0.598 |
| PIVKA (≤400/>400 μg/L) | 69/44 | 21/26 | 0.057 |
| Vascular Invasion (+/-) | 36/77 | 23/24 | 0.041 |
| MVI (Yes/No) | 29/84 | 20/27 | 0.035 |
| MVD (Yes/No) | 19/94 | 9/38 | 0.723 |
| HBsAg (+/-) | 101/12 | 42/5 | 0.997 |
| Direct Bilirubin (≤4/>4) | 53/60 | 17/30 | 0.213 |
| Total Bilirubin (≤10/>10) | 12/101 | 1/46 | 0.073 |
| ALT (≤84/>84 IU/L) | 98/15 | 36/11 | 0.114 |
| TNM (I-II/III-IV) | 82/31 | 31/16 | 0.403 |
| Edmondson stage (H/M/L) | 20/69/24 | 3/34/10 | 0.164 |
| HBV DNA (≤100/>100) | 71/42 | 18/29 | 0.004 |
| NLR (≤1.77/>1.77) | 26/87 | 12/35 | 0.733 |
| INR (≤1/>1) | 42/71 | 15/32 | 0.527 |
| APRI (≤1/>1) | 102/11 | 42/5 | 0.862 |
| HB (≤120/>120) | 13/100 | 4/43 | 0.576 |
| Neutrophil (≤4/>4) | 85/28 | 30/17 | 0.144 |
| Lymphocyte (≤1/>1) | 35/78 | 9/38 | 0.127 |
| PT (≤12/>12) | 63/50 | 23/24 | 0.431 |
| PLT (≤100/>100) | 32/81 | 13/34 | 0.933 |
| AST (≤45/>45) | 72/41 | 22/25 | 0.048 |
| ALB (≤35/>35) | 9/104 | 5/42 | 0.586 |
| ICG (≤10/>10%) | 96/17 | 40/7 | 0.9811 |
P value < 0.05 is Statistically Highly Significant (Pearson Correlation Coefficient); INR, International Normalized Ratio; APRI, AST to platelet ratio index; HB, hemoglobin; PT, prothrombin time; PLT, platelets; AST, glutamic oxaloacetic transaminase; ALB, albumin; ICG, indocyanine green. Bold font is used to describe p<0.05, which is statistically significant.